---
title: "Lipella jumps after inflammatory disease drug found safe in study"
date: "2025-02-11 19:50:24"
summary: "** Shares of Pittsburgh-based drug developer Lipella Pharmaceuticals rise 68.20% to $5.14 premarket ** LIPO says its experimental drug, LP-310, showed a strong safety profile in a small study of 24 patients with oral lichen planus (OLP), a chronic inflammatory disease that affects mucous membranes inside the mouth ** Co..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Shares of Pittsburgh-based drug developer Lipella Pharmaceuticals rise 68.20% to $5.14 premarket

\*\* LIPO says its experimental drug, LP-310, showed a strong safety profile in a small study of 24 patients with oral lichen planus (OLP), a chronic inflammatory disease that affects mucous membranes inside the mouth

\*\* Co says no drug-related serious adverse events were found in study, and no patients dropped out

\*\* LIPO says LP-310, an oral rinse topical treatment, helped meaningfully reduce pain, ulceration, and inflammation for patients in the study

\*\* Co plans to submit marketing application for LP-310 to the FDA in H2Â 2025

\*\* In the last 12 months, the stock has fallen 63.34%

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P20OK:0-lipella-jumps-after-inflammatory-disease-drug-found-safe-in-study/)
